Braveheart Bio, Inc.

424B4 priced

Price $18.00 · 21,250,000 shares · Gross proceeds $382,500,000

CERT inactive

EFFECT effective

8-A12B effective

S-1/A amended

Range $15.00 to $17.00 · 18,750,000 shares

Braveheart Bio, Inc. updates its S-1 filing with enhanced disclosures on intellectual property risks, manufacturing dependencies, and regulatory challenges. The company highlights heightened risks related to reliance on Hengrui for BHB-1893 production, potential supply chain disruptions, and complexities in securing alternative manufacturing pathways outside China. Expanded sections address Bayh-Dole Act implications for government-funded inventions and increased scrutiny of third-party compliance with cGMP standards.

S-1 filed

Braveheart Bio, Inc. is preparing for its IPO, focusing on the development of its lead product candidate, BHB-1893. The company relies heavily on third-party manufacturers, particularly Hengrui, for clinical and commercial supply, exposing it to significant supply chain risks. Intellectual property (IP) licensing challenges, including potential disputes and non-exclusive agreements, pose additional hurdles. Manufacturing scalability, regulatory compliance, and geopolitical disruptions further complicate its path to commercialization. The filing emphasizes risks related to IP rights, dependency on external partners, and the competitive landscape for third-party IP acquisition.

DRS/A amended

DRS filed